Trial record 16 of 16578 for:    "Vascular Diseases"

Open Label Clinical Study to Assess the Clinical Safety of a New Compression Device in Subjects With Peripheral Arterial Vascular Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
3M
ClinicalTrials.gov Identifier:
NCT00854516
First received: February 27, 2009
Last updated: January 20, 2012
Last verified: October 2010
  Purpose

To assess the safety of a new compression device applied to patients with an ankle brachial pressure index (ABPI) 0,5 - 0,8 who are treated for two weeks in daily routine practice. Several perfusion assessments will investigate safety under reduced compression therapy.


Condition Intervention
Peripheral Arterial Vascular Disease
Procedure: A new treatment approach is to have an effective working pressure combined with a low resting pressure.

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open Label Clinical Study to Assess the Clinical Safety of a New Compression Procedure in Subjects With Peripheral Arterial Vascular Disease

Resource links provided by NLM:


Further study details as provided by 3M:

Primary Outcome Measures:
  • The primary objective of this study is to assess the safety of the new compression device in subjects with an ankle brachial pressure index (ABPI) between 0.5-0.8. [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 15
Study Start Date: February 2009
Study Completion Date: January 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: A new treatment approach is to have an effective working pressure combined with a low resting pressure.

    Procedure Schedule: The total duration for study participation will be 14 days (8 visits).

    Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days.

Detailed Description:

Venous leg ulcers represent a very common clinical problem with increasing prevalence in an aging population. It is believed that venous insufficiency is the underlying condition responsible for 54-81% of leg ulcers. About 8% of leg ulcers are related to arterial insufficiency and about 14% have a mixed aetiology. Compression therapy is considered the most effective treatment for these ulcers. The overall cost of chronic venous leg ulcer is high because long term ongoing care is required. Also the quality of life of these patients is jeopardized due to long lasting ulcer treatments and inconvenient compression therapies.

Several compression products are available on the market and there is a large body of literature describing the clinical benefit of different compression systems.

A new treatment approach with the new device is to have an effective working pressure combined with a low resting pressure. A high working pressure achieved by a rigid sleeve around a patient's leg is essential to support the muscle pump, necessary for sufficient blood reflux. However the resting pressure could be low without relevant reduction of compression efficacy but with an increase in safety for patients with a mild to moderate peripheral arterial occlusive disease (PAOD). A high resting pressure is believed to be a main reason for reduced arterial skin perfusion which can result in pressure related skin damage. Accordingly most compression systems are not indicated for patients with an ABPI lower than 0.8. About 25% of patients with chronic venous insufficiency suffer from PAOD and hence are very difficult to treat with compression. With the new device, these patients could be sufficiently treated, because a low resting pressure is believed to have low influence on skin perfusion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females, age 18 years or older.
  2. Subjects suffering from peripheral arterial occlusive disease (PAOD) with an ABPI (ankle brachial pressure index) of the treated leg between 0.5 - 0.8 as measured within up to 4 weeks prior to enrollment. About 5 subjects of the study population should have an ABPI of 0.5.
  3. Subjects who are co-operative, willing to give written informed consent prior to study entry and willing to comply with the study protocol.
  4. Subjects who can walk (with or without a walking aid).

    -

Exclusion Criteria:

  1. Subjects with an ABPI < 0.5 or > 0.8 as measured within up to 4 weeks prior to enrollment.
  2. Subjects whose general condition, in the opinion of the investigator, preclude for compression therapy.
  3. Subjects with paralysis of the study leg
  4. Subjects who started or significantly changed treatment with mood altering substances (e.g. antidepressant drugs) within two weeks prior to enrollment.
  5. Subjects with significant instable coagulopathy; subjects treated with anticoagulant therapeutics can be included.
  6. Subjects who are participating in any prospective clinical study that can potentially interfere with this study.
  7. Subjects who are, in the opinion of the clinical investigator, unsuitable for enrollment in this study, for reasons not specified in the exclusion criteria.
  8. Subjects with known allergies to other materials in the compression device.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00854516

Locations
Germany
Universitaetsklinikum Greifswald
Greifswald, Germany, 17487
Sponsors and Collaborators
3M
Investigators
Principal Investigator: Michael Juenger, Prof. Dr. MD Universitaetsklinikum Greifswald
  More Information

No publications provided

Responsible Party: 3M
ClinicalTrials.gov Identifier: NCT00854516     History of Changes
Other Study ID Numbers: EU Study No-05-000007
Study First Received: February 27, 2009
Last Updated: January 20, 2012
Health Authority: Germany: German Institute of Medical Documentation and Information

Keywords provided by 3M:
compression therapy
3M

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 19, 2014